David Pelizzon Sells 28,834 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Pelizzon sold 28,834 shares of Alphatec stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $21.03, for a total transaction of $606,379.02. Following the completion of the transaction, the director owned 10,645,045 shares in the company, valued at approximately $223,865,296.35. The trade was a 0.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alphatec Trading Up 1.1%

ATEC stock traded up $0.23 during trading on Wednesday, hitting $20.90. 3,368,927 shares of the company traded hands, compared to its average volume of 2,125,982. The firm has a market capitalization of $3.10 billion, a PE ratio of -20.10 and a beta of 1.08. Alphatec Holdings, Inc. has a 1 year low of $8.69 and a 1 year high of $22.66. The company has a 50-day moving average of $18.04 and a 200-day moving average of $14.95. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million during the quarter, compared to analysts’ expectations of $182.78 million. During the same period last year, the firm earned ($0.28) earnings per share. Alphatec’s revenue for the quarter was up 30.4% on a year-over-year basis. Analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alphatec

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATEC. Aster Capital Management DIFC Ltd bought a new position in shares of Alphatec in the 3rd quarter worth about $34,000. Osterweis Capital Management Inc. bought a new stake in Alphatec during the second quarter worth about $37,000. Nisa Investment Advisors LLC boosted its stake in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after acquiring an additional 1,045 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Alphatec in the third quarter worth about $73,000. Finally, FORA Capital LLC purchased a new stake in Alphatec in the first quarter worth about $102,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ATEC shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Alphatec in a report on Monday. Lake Street Capital set a $25.00 price target on Alphatec and gave the company a “buy” rating in a research report on Friday, October 31st. Morgan Stanley set a $23.00 target price on Alphatec in a research note on Tuesday, December 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price target (up previously from $20.00) on shares of Alphatec in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. assumed coverage on shares of Alphatec in a report on Friday, October 24th. They issued an “overweight” rating and a $19.00 price target on the stock. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and an average target price of $22.45.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.